about
Ultra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometryGetting to 90-90-90 in paediatric HIV: What is needed?Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?Measuring adherence to antiretroviral therapy in children and adolescents in western Kenya.Hepatitis infection in the treatment of opioid dependence and abuse.Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.The physical and psychological effects of HIV infection and its treatment on perinatally HIV-infected childrenTherapeutic drug monitoring and human immunodeficiency virus (HIV) antiretroviral therapy.Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimizationEffect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected ChildrenPharmacokinetic optimization of antiretroviral therapy in children and adolescents.Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.Pharmacokinetics of lopinavir determined with an ELISA test in youths with perinatally acquired HIV.Atazanavir-bilirubin interaction: a pharmacokinetic-pharmacodynamic model.Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice?Tetronic® 904-containing polymeric micelles overcome the overexpression of ABCG2 in the blood-brain barrier of rats and boost the penetration of the antiretroviral efavirenz into the CNS.
P2860
Q28474772-0B38F88B-38C9-4EC9-B2E4-C48A65FDA694Q30385352-3BC8B457-CD77-42F3-BF52-2FF1F1271FB9Q33914723-F59B60EA-FDF3-4A17-8811-2B0672851500Q34577449-96669447-ED2F-4AF1-B71D-B4122DBCBA91Q35389163-722664EC-90B7-4CDC-AF0C-A6782BCADE70Q36036400-EAD9B9E0-6CBB-4548-B03C-281A0AAA6F1DQ36349683-80C9DFBA-0D4C-4AF7-A00A-C4A76ADC6B60Q36376533-64C7381C-0214-4531-A150-A36B7686FF10Q37298637-B60FE46D-0CEC-46CF-8B7E-FEA48F368371Q37513856-121AF980-6DC9-47AA-86B3-9A5FF91C7F03Q37835819-EE4C6795-3D3D-4AAB-86AA-C81C2AD09E8DQ40118824-5D266F8E-CA4C-49C2-8E93-46D9030AD17EQ42248475-A94CB35D-1F6F-47EC-A47B-307BD65024DAQ42263920-6015B90A-FC03-4691-8025-9871744FA710Q43699242-5C45BD53-CD0A-4668-847A-64E415397A8AQ45256524-D85BF969-74BF-42D0-BA12-AA23EDA08299Q46904130-025B2608-353A-48C8-B082-E8DE53E5C3CFQ50948205-D398A355-16B8-46DC-BDEB-D21636BBF8BC
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Therapeutic drug monitoring in children with HIV/AIDS.
@ast
Therapeutic drug monitoring in children with HIV/AIDS.
@en
type
label
Therapeutic drug monitoring in children with HIV/AIDS.
@ast
Therapeutic drug monitoring in children with HIV/AIDS.
@en
prefLabel
Therapeutic drug monitoring in children with HIV/AIDS.
@ast
Therapeutic drug monitoring in children with HIV/AIDS.
@en
P2093
P1476
Therapeutic drug monitoring in children with HIV/AIDS.
@en
P2093
David M Burger
Pieter L A Fraaij
Ronald de Groot
P304
P356
10.1097/00007691-200404000-00006
P577
2004-04-01T00:00:00Z